이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

Liposomal Bupivacaine Plus Plain Bupivacaine Versus Dexamethasone Plus Plain Bupivacaine in the Supraclavicular Brachial Plexus Block in Patients With Risk Factors for Severe Acute Postoperative Pain

2026년 9월 3일 업데이트: Wong Sau Ching Stanley, The University of Hong Kong

Liposomal Bupivacaine Plus Plain Bupivacaine Versus Dexamethasone Plus Plain Bupivacaine in the Supraclavicular Brachial Plexus Block in Patients With Risk Factors for Severe Acute Postoperative Pain: a Randomized Controlled Trial

The supraclavicular brachial plexus block (BPB) is a frequently used anaesthetic method for upper limb surgeries, including distal radial fracture surgery. Adding liposomal bupivacaine to BPB has shown promise in enhancing postoperative pain control. A previous randomized controlled trial demonstrated that it reduced pain scores and OBAS compared to plain bupivacaine alone, especially on postoperative day (POD) 1. Adding adjuncts to non-liposomal local anaesthetics can also enhance and prolong postoperative pain relief. The effectiveness of liposomal bupivacaine compared to adjuncts like dexamethasone and dexmedetomidine remains unclear. Since liposomal bupivacaine is more expensive, it is crucial to compare its analgesic efficacy with these alternatives. A randomized controlled trial comparing liposomal bupivacaine versus dexamethasone in the interscalene BPB for shoulder surgery found that liposomal bupivacaine resulted in statistically significantly lower pain scores and less pain interference in the Brief Pain Inventory, although the reduction was not considered clinically relevant. Its high cost may therefore limit its routine use unless specific clinical contexts where its efficacy is maximized are identified. Notably, patients with risk factors like psychological factors, preoperative pain, and prior analgesic use may benefit most from its application.

A randomized controlled trial to compare the analgesic efficacy of liposomal bupivacaine plus plain bupivacaine versus dexamethasone plus plain bupivacaine in supraclavicular BPB for patients at higher risk of poor acute pain control post distal radial fracture surgery will be conducted. Patients with severe preoperative pain, opioid use, depressive symptoms, anxiety symptoms, and/or higher energy and high-grade fracture cases will be selected. The primary outcome measured is the intensity of acute postoperative pain with movement in the first 48 hours after surgery. Important secondary outcomes include pain intensity at rest, opioid consumption, OBAS scores, chronic pain, and upper limb functionality.

연구 개요

연구 유형

중재적

등록 (추정된)

90

단계

  • 3단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

  • 이름: Stanley S.C. Wong
  • 전화번호: (852) 2255 3303
  • 이메일: wongstan@hku.hk

연구 장소

      • Hong Kong, 홍콩
        • 모병
        • Queen Mary Hospital
        • 연락하다:
          • Stanley S.C. Wong
          • 전화번호: (852) 2255 3303
          • 이메일: wongstan@hku.hk

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

  • 성인
  • 고령자

건강한 자원 봉사자를 받아들입니다

아니

설명

Inclusion Criteria:

  • American Society of Anesthesiologist (ASA) status I-III
  • Age 18-90 years old
  • Scheduled for distal radial fracture fixation (Open reduction and internal fixation with volar approaching locking plate)
  • Informed consent obtained
  • Patients identified to be at an elevated risk of suffering from poor postoperative pain control. Patients with one or more of the following risk factors:

    • Severe preoperative pain: defined as worse numerical rating scale (NRS) pain score equal or higher than 6/10 with arm movements at day before surgery.
    • Preoperative use of opioid: use of strong opioids such as morphine, oxycodone
    • Depressive symptoms: Patient health questionnaire (PHQ-9) score of 10 or above
    • Anxiety symptoms: General Anxiety Disorder (GAD-7) score of 10 or above
    • Higher energy and high-grade fracture cases - road traffic accident, fall from height, open fractures, combined distal radius and distal ulna fractures, fractures requiring external fixation, fractures with severe articular comminution or severe metaphyseal extension, comminuted fractures requiring more than a single volar approach incision and a single volar locking plate implant

Exclusion Criteria:

  • Revision surgery
  • Previous fractures or surgery in the affected distal radius
  • Surgery involving more than the affected arm
  • Cases with baseline (pre-injury) QuickDASH score worse (higher) than 10 out of 100
  • Respiratory compromise (requires long term oxygen)
  • History of seizures
  • Pre-existing neurological disorder/deficit
  • Alcohol or substance abuse
  • Impaired mental state
  • Local infection
  • Allergy to analgesic drugs: local anaesthetic drugs, paracetamol, non-steroidal anti-inflammatory drugs (NSAIDs), opioids
  • Impaired renal function (defined as effective glomerular filtration rate < 30ml/min/1.73m2
  • Impaired liver function (defined as plasma bilirubin over 34μmol/L; international normalized ratio [INR] ≥1.7, alanine aminotransferase [ALT] over 100U/L, aspartate aminotransferase [AST] over 100U/L)
  • Coagulopathy (platelet count <100,000/ml and/or INR ≥ 1.5) or the use of anticoagulants (not including aspirin) that precludes the use of supraclavicular BPB
  • Pregnancy
  • Patient refusal for regional nerve blocks
  • Patient refusal to join the clinical trial
  • Patient unable/unwilling to attend post-op rehabilitation programme

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 삼루타

무기와 개입

참가자 그룹 / 팔
개입 / 치료
활성 비교기: SBPB using 10ml 0.5% plain bupivacaine with 10ml 1.33% liposomal bupivacaine (LP-BPB)
Supraclavicular brachial plexus block with 10ml 0.5% plain bupivacaine plus 10ml 1.33% liposomal bupivacaine
10ml 0.5% plain bupivacaine plus 10ml 1.33% liposomal bupivacaine (133mg)
실험적: SBPB using 19ml 0.5% plain bupivacaine with 1ml (4mg) dexamethasone (D-BPB)
Supraclavicular brachial plexus block using 19ml 0.5% plain bupivacaine plus 1ml (4mg) dexamethasone
19ml 0.5% plain bupivacaine plus 1ml (4mg) dexamethasone

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Weighted area under curve (AUC) pain score with movement
기간: The first 48 hours after surgery
The weighted area under curve (AUC) numerical rating scale (NRS) pain score with movement (active wrist flexion and extension) from 0-48 hours after distal radial fracture surgery.
The first 48 hours after surgery

2차 결과 측정

결과 측정
측정값 설명
기간
NRS pain scores
기간: Postoperative day 0-7
NRS pain scores both at rest and with movement will be assessed from after surgery to POD 7. (NRS scale 0-10, where 0 is no pain, and 10 is the worst possible pain)
Postoperative day 0-7
Overall Benefit of Analgesic Score (OBAS)
기간: Postoperative day 0-7
Overall Benefit of Analgesic Score (OBAS) will be assessed once a day until POD 7 (range, 0 [best] to 28 [worst]).
Postoperative day 0-7
Acute postoperative opioid consumption
기간: Postoperative day0-7
The daily consumption of oxycodone in the ward and after discharge will be recorded. The dose of rescue intravenous morphine consumption in the PACU will also be recorded.
Postoperative day0-7
Sleep disturbance
기간: Postoperative day0-7
Sleep disturbance due to pain will be evaluated once a day till POD 7 (0-10, where 0 represents no disturbance and 10 represents the most disturbance possible).
Postoperative day0-7
Quality of recovery (QoR)
기간: Postoperative day0-7
This will be accessed using the Quality of recovery (QoR) questionnaire. (range from 0 to 18, where 0 represent the worst quality of recovery and 18 represent the best quality of recovery)
Postoperative day0-7
Adverse effects related to supraclavicular BPB
기간: postoperative day0-2
The potential side effects related to the supraclavicular BPB will be recorded.
postoperative day0-2
Opioid related side effects
기간: postoperative day0-7
Opioid related side effects will be recorded.
postoperative day0-7
Analgesic block duration.
기간: On postoperative day1
Time to return of pain, time to sensory resolution, time to motor resolution will be recorded on POD 1.
On postoperative day1
Sensory and motor assessment of the affected upper limb
기간: Postoperative day0-1
Sensation to pin prick will be tested over the following areas: C5 (lateral shoulder), C6 (thumb), C7 (3rd finger), and C8 (4th finger) dermatomes. Motor assessment will be done by recording grip strength and bicep contraction. Sensation will be rated as 0-10 , where 0 represent no sensation and 10 represent normal sensation. Motor function will be rated as 0 (paralysis), 1 (paresis), 2 (normal power).
Postoperative day0-1
Health related quality of life
기간: Baseline and at 3, 6 and 12 weeks after surgery
Health related quality of life will be assessed using the SF-12v2. Baseline scores will be obtained before surgery. The SF-12v2 will produce two summary scores: the Physical Component Summary (PCS) and the Mental Component Summary (MCS). Both summary scores range from 0 to 100, where higher scores always indicate better physical and mental health.
Baseline and at 3, 6 and 12 weeks after surgery
Upper limb functional scores.
기간: Baseline and at 3, 6 and 12 weeks after surgery
The validated Chinese versions of the Disabilities of the Arm, Shoulder, and Hand (QuickDASH) will be used to assess upper limb functional scores. Baseline scores will be obtained before surgery. (Range from 0 to 100, a lower score indicates a better outcome)
Baseline and at 3, 6 and 12 weeks after surgery
Hand grip power of normal and injured side
기간: At 3, 6 and 12 weeks after surgery
Hand grip power of normal and injured side will be assessed (both hands).
At 3, 6 and 12 weeks after surgery

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2026년 8월 4일

기본 완료 (추정된)

2028년 9월 1일

연구 완료 (추정된)

2029년 3월 1일

연구 등록 날짜

최초 제출

2026년 6월 11일

QC 기준을 충족하는 최초 제출

2026년 6월 18일

처음 게시됨 (실제)

2026년 6월 24일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 9월 8일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 9월 3일

마지막으로 확인됨

2026년 9월 1일

추가 정보

이 연구와 관련된 용어

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다